LRRK2 Kinase Inhibition Rescues Deficits in Lysosome Function Due to Heterozygous GBA1 Expression in Human

Anwesha Sanyal1, Hailey S Novis1, Emile Gasser1

  • 1Ann Romney Center for Neurological Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

Insights

Parkinson's disease linked genes LRRK2 and GBA1 show crosstalk. LRRK2 kinase inhibition partially corrects lysosomal defects and alpha-synuclein issues in GBA1-deficient neurons.

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • Parkinson's disease (PD) pathogenesis involves genes regulating lysosome function, notably LRRK2 and GBA1.
  • LRRK2 mutations are a common genetic cause of PD, linked to increased kinase activity.
  • GBA1 mutations significantly elevate PD risk, affecting lysosomal function.

Purpose of the Study:

  • To investigate the physiological crosstalk between LRRK2 signaling and glucocerebrosidase activity in human neurons.
  • To elucidate the impact of GBA1 deficiency on lysosomal function and alpha-synuclein in human neurons.
  • To determine the effects of LRRK2 kinase inhibition on lysosomal abnormalities in GBA1-deficient neurons.

Main Methods:

  • Utilized human induced pluripotent stem cell (iPSC)-derived neurons.
  • Studied GBA1-heterozygous-null neurons to assess lysosomal morphology and function.
  • Quantified alpha-synuclein accumulation and secretion.
  • Administered LRRK2 kinase inhibitors to evaluate their effects on lysosomal dysfunction.

Main Results:

  • Allelic loss of GBA1 caused widespread defects in lysosomal morphology and function in human neurons.
  • GBA1-deficient neurons exhibited increased accumulation and secretion of oligomeric alpha-synuclein.
  • LRRK2 kinase inhibition normalized several indices of lysosomal dysfunction, though some defects persisted.

Conclusions:

  • A selective, functional intersection exists between glucocerebrosidase (GBA1) dysfunction and LRRK2 signaling in human neurons.
  • LRRK2 kinase inhibition demonstrates therapeutic potential for GBA1-related lysosomal dysfunction in Parkinson's disease.
  • Findings provide insights into Parkinson's disease pathogenesis and potential therapeutic strategies targeting LRRK2/GBA1 pathways.